Kornimate/medical-research-clean huggingface dataset:
a pilot study to determine the efficacy of intravenous ibuprofen for pain control following arthroscopic knee surgery

Conditions: Arthroscopic Knee Surgery

Summary: the intent of this study is to assess the analgesic efficacy of iv ibuprofen when administered at induction of anesthesia. results from this pilot study will be used to design and determine the appropriate statistical power for a larger, multi-center randomized study.

non-steroidal anti-inflammatory drugs(nsaids) are an effective adjunct to opioid analgesia for moderate-severe pain, with improvement in the quality of pain relief and consistent evidence of opioid dose sparing. nsaids alone could provide effective analgesia post-surgery when mild-moderate pain is expected. there is also evidence that the use of nsaids, by avoiding or decreasing the need for opioids, can lead to a reduction in the incidence of adverse events which are commonly attributed to, or exacerbated by, opioids. the intent of this study is to assess the analgesic efficacy of iv ibuprofen when administered at induction of anesthesia. results from this pilot study will be used to design and determine the appropriate statistical power for a larger, multi-center randomized study.

Eligibility criteria:
inclusion criteria: * patients scheduled for knee arthroscopy exclusion criteria: * inadequate intravenous (iv) access. * history of allergy or hypersensitivity to any component of ibuprofen or other nsaids, aspirin (or aspirin related products), opioids or cyclooxygenase-2(cox-2) inhibitors. * less than 18 years of age. * use of analgesics less than 8 hours prior to surgery. * patients with active, clinically significant anemia. * history or evidence of asthma or heart failure. * pregnant. * recent history of chronic non-steroidal anti-inflammatory drug (nsaid) or opioid use. * inability to understand the requirements of the study, be willing to provide written informed consent (as evidenced by signature on an informed consent document approved by an institutional review board \[irb\]), and agree to abide by the study restrictions and to return for the required assessments. * refusal to provide written authorization for use and disclosure of protected health information.

Keywords: knee surgery, arthroscopy; orthopaedic, orthopedic surgery
study to evaluate the safety, efficacy and pharmacokinetics of teduglutide in japanese subjects with pn-dependent short bowel syndrome (sbs)

Conditions: Short Bowel Syndrome

Summary: the purpose of this study is to evaluate the safety and efficacy of an investigational treatment (teduglutide) in japanese patients with pn-dependent sbs. this study will also look at how teduglutide moves through the body (pharmacokinetics).


Eligibility criteria:
this study has 3 stages, consisting of an optimization/stabilization period (stage 1), a 24-week treatment period in which all patients will receive teduglutide (stage 2), and a long-term extension (stage 3). during the long-term extension (stage 3), patients will continue to receive teduglutide for up to an additional 24 months or until teduglutide is commercially available, whichever comes earlier.
study evaluating safety and efficacy of ucart targeting cs1 in patients with relapsed/refractory multiple myeloma (melani-01)

Conditions: Relapsed/Refractory Multiple Myeloma

Summary: this is a phase i, fih, open-label, dose escalation study evaluating safety and efficacy of ucart targeting cs1 in patients with relapsed or refractory multiple myeloma (mm). the purpose of this study is to evaluate the safety and clinical activity of ucartcs1a and to determine the maximum tolerated dose (mtd).


Eligibility criteria:
inclusion criteria: * patients with confirmed diagnosis of active multiple myeloma (as defined by international myeloma working group \[imwg\] criteria) who have relapsed/refractory disease after and have received at least 3 prior lines of prior therapy. * eastern cooperative oncology group performance status of 0 or 1; * no previous treatment with investigational gene targeting cs1 or chimeric antigen receptor therapy targeting cs1 * adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within the screening period. * other criteria may apply. exclusion criteria: * previous treatment with investigational gene therapy targeting cs1 or chimeric antigen receptor therapy targeting cs1; * any cellular therapy (other than autologous or allogenic hsct) within 60 days prior to enrollment; * prior treatment with rituximab or other anti-cd20 therapy within 3 months * any known active or uncontrolled infection * autologous hematopoietic stem cell transplantation (hsct) within 12 weeks prior to enrollment; any cellular therapy (other than autologous) within 60 days prior to enrollment; prior allogeneic hsct. * seropositive for hepatitis c virus or positive for hepatitis b surface antigen or core antibody. * presence of active and clinically relevant central nervous system disorder, such as epilepsy, generalized seizure disorder, paresis, aphasia, stroke, severe brain injury, dementia, parkinson's disease, cerebellar disease, or organic brain syndrome.

Keywords: multiple myeloma chimeric antigen receptor t-cell (cart-t) therapy transcription activator-like effector nuclease (talen) allogeneic
a comprehensive study to isolate tumor-initiating cells from human epithelial malignancies

Conditions: Bladder Cancer; Skin Cancers; Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)

Summary: we hypothesize that all human malignancies harbour a subpopulation of tumor initiating cells/cancer stem cells (cscs) that drives tumor development and potentially recurrence or metastasis of the disease. the primary aim of this study is to develop strategies for prospective isolation/enrichment of cscs from human tumors of different tissue origins. in addition, we will characterize the signaling pathways and/or tumor specific antigens that are specific for cscs, in order to specifically target these cscs as the endpoint of this study.


Eligibility criteria:
inclusion criteria:n/a. we will recruit all non-melanoma skin and bladder cancer patients that are recommended for surgical removal of tumor tissues. this includes patients from all ages, gender and ethnicity background. our sample collection criteria based on the tumor size of individual (e.g. tumor samples will only be collected if it will not affect the pathological diagnosis or treatment procedures of patients). exclusion criteria:n/a
establishment of abbreviated pancreatobiliary mri protocol

Conditions: Pancreas Cyst; Intraductal Papillary Mucinous Neoplasm

Summary: this study aims to establish abbreviated pb mri protocol for patients on regular imaging follow-up for pancreas cystic neoplasm.


Eligibility criteria:
inclusion criteria: * on follow-up for pancreas intraductal mucinous neoplasm * or incidentally detected pancreas cyst (equal to or larger than 1cm) * and scheduled for cect or has cect within a months * and sign informed consent exclusion criteria: * any absolute or relative contra-indication for contrast-enhanced mri * no pancreas cystic neoplasm * history of pancreatectomy * history of any procedure for pancreatic cyst (ablation, aspiration...) in a year * hemosiderosis * suspicion of acute pancreatitis

Keywords: mri
a study of ly4086940 in healthy participants and participants with overweight or obesity, with or without type 2 diabetes

Conditions: Healthy; Overweight; Obesity; Type 2 Diabetes

Summary: the main purpose of this study is to evaluate the safety, tolerability of ly4086940 and how it is processed in the body. participation in part a of the study will last about 10 weeks and may include up to 6 visits. participation in parts b, c, d will last approximately 15 weeks and may include up to 9 visits.


Eligibility criteria:
inclusion criteria: * have no significant body weight change for the 3 months prior to screening part a: * are considered healthy * have a body mass index (bmi) of 22 to 35 kilograms per square meter (kg/m2) at screening part b: * have a bmi of 27 to 45 kg/m2 at screening part c: * have a bmi of 25 to 45 kg/m2 at screening part d: * have type 2 diabetes * have hemoglobin a1c (hba1c) ≥7.0% and ≤10.5% at screening * have a bmi of 27 to 45 kg/m2 at screening exclusion criteria: * have had an acute cardiovascular condition within the past 6 months prior to screening * have liver disease or pancreatitis * have used medications for weight loss within the 3 months prior to screening parts a, b, c: * have any form of diabetes part d: * have type 1 diabetes

Keywords: oral incretin weight loss overweight obesity diabetes
the effects of hemodialysis on serum sclerostin levels

Conditions: Diabetes Mellitus; Renal Failure; Hemodialysis Access Failure

Summary: background: parathyroid hormone (pth) and 1,25-dihydroxy vitamin d (1,25-ohd) as well as mineral bone metabolism modulators like sclerostin are thought to play an important role in in diabetic patients with chronic renal failure. the present study aimed to analyse the levels of serum sclerostin before and after hemodialysis which is a primary element of treatment in such combined disease states. methods: serum sclerostin concentrations were measured using a commercially available enzyme-linked immunosorbent assay kit with 56 individuals who 14 chronic hemodialysis patients with diabetes, 14 chronic hemodialysis patients with non-diabetes and 28 healthy volunteers as a control group.

sclerostin results in a phenotype characterized by high bone mass (sclerosteosis) in humans, it is produced by osteocytes and chondrocytes, it suppresses osteoblast activity by inhibiting canonicular wnt / β-catenin signal, it is described as an anti-anabolic protein of 22-kda size.in diabetes mellitus patients osteoporosis and obesity always create problems, increased levels of sclerostin inhibit canonicular wnt / β-catenin signal and is potentially held responsible from bone fragility. bone problems are important both for chronic kidney disease patients and diabetes mellitus patients and in instances where these two diseases coexist, the importance of sclerostin as a new marker of bone turnover increases. the objective of this study is to evaluate how serum sclerostin levels are affected in diabetes mellitus patients undergoing hemodialysis treatment. to this end, the investigators analyzed the levels of serum sclerostin before and after hemodialysis as it is a main element of treatment in such combined disease states.

Eligibility criteria:
inclusion criteria: * patients who satisfied inclusion criteria signed informed consent forms before they enrolled in the study. * chronic hemodialysis patients receiving treatment at our hospital. * the patients had type 2 diabetes mellitus and the patients were not diabetic. * healthy volunteers as a control group exclusion criteria: * clinical diagnosis of chronic respiratory failure, acute kidney failure, nephrotic syndrome, end-stage liver disease, malignancy, acute infections * any health problems necessitating urgent interventions, drinking alcohol and/or smoking as well as pregnant patients

Keywords: diabetes mellitus renal failure hemodialysis access failure sclerostin
glycaemic control and quality of care in type 2 diabetes on novomix® 30 previously treated with mixtard® insulins

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this observational study is conducted in europe. the objective of this retrospective observational cohort analysis is to assess the changes of glycaemic control and quality of care in those type 2 diabetic patients who were previously treated with mixtard® insulins after 6 months of their switch to analog premix insulin novomix® 30 therapy.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with type 2 diabetes previously treated with bhi for at least 12 months * analogue premix administration for the last 6 months exclusion criteria: * known or suspected allergy to insulin aspart * newly diagnosed diabetes
covid-19 and vitamin d in nursing-home

Conditions: Coronavirus

Summary: first epidemiological data about covid-19 pandemic confirm that older adults are likely to experience severe and lethal forms of sars-cov-2 infection, in particular frail elderly living in nursing-homes. vitamin d could be a biological determinant of covid-19, as indicated by genomic-guided tracing of sars-cov-2 targets in human cells. epidemiological observational data are necessary for better understanding the links between vitamin d supplementation and covid-19 outcomes, in particular in nursing-homes (in which the risk of hypovitaminosis d is very high). the investigators had the opportunity to use information collected in a french middle-sized nursing-home affected by covid-19 in march-april 2020, to determine whether recent vitamin d3 supplementation was associated with the prognosis of covid-19 in residents infected with sars-cov-2. as recommended in french nursing-homes, all residents are systematically and regularly supplemented with bolus vitamin d3 (every single, 2 or 3 months, depending on residents). the main objective of this study is to determine whether bolus vitamin d3 supplementation taken during or in the month before covid-19 was effective in improving survival among frail elderly nursing-home residents infected with covid-19 compared to those having received supplementation longer ago. the secondary objective is to determine whether bolus vitamin d3 supplementation taken during or in the month before covid-19 was effective in limiting the clinical severity of the infection according to the world health organization's ordinal scale for clinical improvement (osci) for covid-19 compared to those having received supplementation longer ago.

retrospective observational unicentric study in nursing-home residents with covid-19. health status monitoring data available until may 15, 2020. for all participants, gender, age, disability, history and comorbidities, treatments, date of last vitamin d3 supplementation, results of last blood test, date of suspicion / diagnosis of covid-19, covid-19 osci score, and eventual hospitalization or death (surveillance data available until may 15, 2020) are collected.

Eligibility criteria:
inclusion criteria: * living in the nursing-home of saint laurent-de-chamousset, france, during the covid-19 epidemic (march-april 2020) * being suspected or diagnosed with covid-19 (rt-pcr, chest ct scan) exclusion criteria: - opposition of the resident and/or relatives to the use of anonymized clinical-biological data
to evaluate the efficacy of ddb/garlic oil in patients with elevated transaminase chronic liver disease

Conditions: Chronic Liver Disease

Summary: purpose - to evaluate the efficacy of biphenyl dimethyl dicarboxylate(ddb)/garlic oil in patients with elevated transaminase chronic liver disease.

biphenyl dimethyl dicarboxylate (ddb) combined with garlic oil (pennel) has been used to treat chronic liver disease. a randomized, double-blind, active- and placebo-controlled clinical trial was conducted to investigate the efficacy, safety and quality of life in chronic liver disease patients.

Eligibility criteria:
inclusion criteria: * patients over 20years of age * patients with more 60 alt in screening period. * to evaluate alt and ast at least three months. * serum transaminase abnormal(before 6months), chronic liver disease or fatty liver, liver disease medical treatment at more than 30days * women of childbearing age get her consent for contraception, pregnancy urine test result negative. exclusion criteria: * alt\>10unl on screening period. * current treatment on another clinical trial * pregnancy or breastfeeding
dexmedetomidine infusion impact on chronic pain patients

Conditions: Chronic Pain

Summary: chronic pain (cp) was defined as pain experienced daily or on most days and induced restriction of at least one activity. cp is one of the commonest complaints confronted in outpatient clinics and constitutes a challenge for all medical provisions. cp is a multifaceted condition; postoperative cp is frequently encountered in clinical practice and may be of debilitating severity leading to worse quality of life (qol) especially cp with a neuropathic component as post-mastectomy pain syndrome and post-amputation pain and chronic post-sternotomy pain that seriously impacts patients' qol and affects patient recovery till 12 months after cardiac surgery. chronic musculoskeletal pain as defined by the international pain association is the persistent or recurrent pain involving spine, bones, joints, and/or musculo-soft tissue. chronic pain was considered as a long-lasting stressor that might induce disordered mood varying between depression and anxiety with consequent challenge of this combination on treatment outcomes and consumption of health resources. this necessitated psychological screening of cp patient to identify and manage patients with disordered mood to improve cp treatment outcomes.


Eligibility criteria:
inclusion criteria: * patients with multiple-level spinal canal stenosis who refused surgical management. exclusion criteria: * patients with other causes for cp; * maintained on opioid analgesia; * had cardiac lesions; * maintained on antihypertensive therapy; * hepatic impairment; * patients can't attend the clinic to complete the course of dexmedetomidine infusion sessions.
effects of propofol on brain function in patients with parkinson's disease

Conditions: PD - Parkinson's Disease

Summary: propofol is a short-acting general anesthetic drug commonly used in clinical practice, with rapid clinical onset of action, amnesic, anxiolytic, antiepileptic, and muscle relaxant effects. the lack of natural antioxidants in patients with parkinson's disease and propofol's ability to protect the brain by inhibiting oxidative stress, its pharmacokinetic and pharmacodynamic properties make propofol a suitable anesthetic drug for functional stereotactic surgery in patients with parkinson's disease. however, changes in brain functional status during propofol anesthesia in parkinson's patients are unknown. there is a lack of data from extensive clinical studies to support the need for propofol dosing during induction of anesthesia compared with non-parkinson patients. this study is a prospective cohort study designed to compare the differences in propofol dosing requirements during induction of propofol anesthesia in patients with pd versus non-pd and to monitor the characteristics of altered brain functional status such as eeg and cerebral blood flow autoregulation capacity in pd versus non-pd patients during the perioperative period.


Eligibility criteria:
inclusion criteria: pd group: 1. age 18-80 years, asa class i-iii, proposed bilateral dbs surgery; 2. primary pd, or hereditary pd, various genotypes of pd, responding well to compounded levodopa; 3. informed consent obtained; non-pd group: 1. age 18-80 years, asa class i-iii, proposed non-neurosurgical non-cardiac surgery; 2. no previous clearly diagnosed neurological disease or neurological dysfunction; 3. informed consent obtained. exclusion criteria: 1. obstructive sleep apnea; 2. bmi \> 30kg/m2; 3. estimated difficult airway; 4. patients with prior allergy to anesthetic drugs; 5. serious dysfunction of important organs (i.e. heart failure, renal or liver dysfunction); 6. patients with craniocerebral trauma or craniocerebral operation history resulting in incomplete skull or brain parenchyma defect; 7. patients with alcohol or drug addiction.

Keywords: propofol electroencephalography cerebral autoregulation
efficacy of digital otoscope and otoendoscope for diagnosis of middle ear pathology

Conditions: Middle Ear Disease; Diagnosis

Summary: for diagnosis of external and middle ear diseases, an otoscope is a key instrument to use. a microscope has been used as a reference standard to confirm pathology. an endoscope has been also widely used. both microscope and endoscope provide an excellent image quality, can record and capture the images, and the images can be visualized with an export system. a digital otoscope is widely available and more affordable. a comparative study of the efficacy of the endoscope and the digital endoscope will be performed.

a comparative study for the diagnosis of middle ear disease usingteslong digital otoscope, model ms450d39, and the otoendoscope will be performed. the participants will be recruited at the ent clinic, university hospital. a handheld otoscope will be used to identify the patients who have the pathology of the middle ear. the images will be captured with both endoscopes and will be reviewed by staff, residents training in ent, and residents training in ent and family medicine.

Eligibility criteria:
inclusion criteria: * patients who were diagnosed with middle ear disease after examination by conventional otoscope at ent clinic, chiang mai university hospital * had otoscopic examination with both digital otoscope and otoendoscope in the same visit in one ear or both ears exclusion criteria: * having abnormal external ear canals such as external auditory canal stenosis, otitis external, otomycosis, or pus/ debris in the ear canal that obscures the view of the eardrum * changing the pathology of the ear canal or middle ear in the same visit * trauma after otoscopic examination * can not record or focus the entire view of the eardrum by both otoscopes

Keywords: middle ear disease otoscope diagnosis
liver cancer community education

Conditions: Liver Cancer

Summary: this study proposes to bridge the gap between evidence and action and combat rising liver cancer rates attributed to hepatitis b and c infection in philadelphia by identifying neighborhoods with higher than expected rates of liver cancer and related risk factors and administering an educational intervention about liver cancer and neighborhood health in those communities, working with existing community partners at fox chase cancer center.


Eligibility criteria:
inclusion criteria: * speaks/reads english * lives in philadelphia or receives healthcare at a community partner site in philadelphia exclusion criteria: * none

Keywords: prevention education